ImmuFact IMP321: Phase I started

Immutep began a single-arm, open-label, historically-controlled, Swiss Phase I trial in 9 patients of IMP321 as an adjuvant. After undergoing chemotherapeutic lymphodepletion and adoptive T cell trans...